mTADA: a framework for analyzing de novo mutations in multiple traits

Author List:

Hoang T. Nguyen¹, Amanda Dobbyn^{1,2}, Joseph Buxbaum³, Dalila Pinto^{3,4,5}, Shaun M Purcell⁶, Patrick F Sullivan⁷, Xin He⁸, Eli A. Stahl^{1,9}

Author Affiliations:

1. Division of Psychiatric Genomics, Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
2. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
3. Seaver Autism Center, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
4. The Mindich Child Health & Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
5. Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
6. Sleep Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
7. Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, North Carolina, USA.
8. Department of Human Genetics, University of Chicago, Chicago, IL, USA.
9. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Abstract

Joint analysis of multiple traits can result in the identification of associations not found through the analysis of each trait in isolation. In addition, approaches that consider multiple traits can aid in the characterization of shared genetic etiology among those traits. In recent years, parent-offspring trio studies have reported an enrichment of *de novo* mutations (DNMs) in neuropsychiatric disorders. The analysis of DNM data in the context of neuropsychiatric disorders has implicated multiple putatively causal genes, and a number of reported genes are shared across disorders. However, a joint analysis method designed to integrate *de novo* mutation data from multiple studies has yet to be implemented. We here introduce multiple-trait TADA (mTADA) which jointly analyzes two traits using DNMs from non-overlapping family samples. mTADA uses two single-trait analysis data sets to estimate the proportion of overlapping risk genes, and reports genes shared between and specific to the relevant disorders. We applied mTADA to >13,000 trios for six disorders: schizophrenia (SCZ), autism spectrum disorder (ASD), developmental disorders (DD), intellectual disability (ID), epilepsy (EPI), and congenital heart disease (CHD). We report the proportion of overlapping risk genes and the specific risk genes shared for each pair of disorders. A total of 153 genes were found to be

shared in at least one pair of disorders. The largest percentages of shared risk genes were observed for pairs of DD, ID, ASD, and CHD (>20%) whereas SCZ, CHD, and EPI did not show strong overlaps in risk gene set between them. Furthermore, mTADA identified additional SCZ, EPI and CHD risk genes through integration with DD *de novo* mutation data. For CHD, using DD information, 31 risk genes with posterior probabilities > 0.8 were identified, and 20 of these 31 genes were not in the list of known CHD genes. We find evidence that most significant CHD risk genes are strongly expressed in prenatal stages of the human genes. Finally, we validated our findings for CHD and EPI in independent cohorts comprising 1241 CHD trios, 226 CHD singletons and 197 EPI trios. Multiple novel risk genes identified by mTADA also had *de novo* mutations in these independent data sets. The joint analysis method introduced here, mTADA, is able to identify risk genes shared by two traits as well as additional risk genes not found through single-trait analysis only. A number of risk genes reported by mTADA are identified only through joint analysis, specifically when ASD, DD, or ID are one of the two traits examined. This suggests that novel genes for the trait or a new trait might converge to a core-gene list of the three traits.

1. Introduction

The analysis of multiple traits can help characterize the genetic architectures of complex disorders (Solovieff, et al., 2013). One approach is to meta-analyze results derived from separate single-trait studies (Zhernakova, et al., 2011). However, joint analysis with multiple traits can better accommodate heterogeneity of genetic effects of the same variants or genes across traits (Allison, et al., 1998; Galesloot, et al., 2014). Numerous studies have jointly analyzed two or more traits and successfully identified shared common-variant associations (Giambartolomei, et al., 2014; Pickrell, et al., 2016; Lutz, et al., 2017; Turley, et al., 2018); however, none of these studies has examined rare variation from case-control (CC) data, or *de novo* variants for which mutations rates should be taken into account. For these rare variants, gene based tests have successfully identified genes associated with different disorders (He, et al., 2013; De Rubeis, et al., 2014; Iossifov, et al., 2014; Nguyen, et al., 2017). Some recent studies have also shown that there are multiple risk genes that are shared between neurodevelopmental disorders (Hoischen, et al., 2014; Li, et al., 2016; Nguyen, et al., 2017), and also with congenital heart disease (CHD) (Homsy, et al., 2015; Willsey, et al., 2018). These results are based on the intersection among the top prioritized genes from each disorder; therefore, reported numbers of genes shared by multiple disorders remain low (Nguyen, et al., 2017; Willsey, et al., 2018). Development of multi-trait rare-variant methods for neuropsychiatric disorders (NPDs) and related disorders will facilitate the understanding of this important aspect of genetic architecture for these phenotypes.

Currently, there is still a limitation in the risk gene identification for a single trait of NPDs and relevant disorders. One reason is that risk gene discovery is underpowered when sample sizes are limited, as well as when relative risks (RRs) are not large (He, et al., 2013; Nguyen, et al., 2017). Multiple risk genes have been reported for developmental disorders (DD), intellectual disability (ID) and autism spectrum disorder (ASD) (De Rubeis, et al., 2014; Lelieveld, et al., 2016; Deciphering Developmental Disorders Study, 2017) thanks to large sample sizes and/or RRs (Nguyen, et al., 2017). However, there are a few risk genes identified for schizophrenia (SCZ) and epilepsy (EPI) because of small RRs and small sample size respectively (Nguyen, et al., 2017). Simply increasing sample size is an expensive solution and might not be feasible for some

rare disorders. If the genetics overlap, methods that can leverage the information from one trait to increase power for risk-gene identification for another trait with smaller sample size or RRs could help in obtaining additional genes for these disorders.

Here, we have developed a new statistical model that combines *de novo* mutation information to identify shared and specific risk genes for two disorders. To illustrate the advantage of the new pipeline over its previous single-trait version, we have applied the pipeline to a large data set of different NPDs and CHD (~13,000 parent-offspring trios) and identified shared genes between each pair of these disorders. We have also used this pipeline to identify additional risk genes for each disorder by borrowing the information of other traits. The identification of shared genes is important for understanding the overlapping genetic information of these disorders.

2. Methods

2.1 The mTADA pipeline

2.1.1 Statistical models in mTADA

We developed the **multi-trait Transmission And Denovo Association (mTADA)** pipeline to analyze DNMs for any two given disorders using the computational framework of extTADA (Nguyen, et al., 2017) (Table 1). The mTADA pipeline is gene-based and requires input data of the number of *de novo* mutations and mutation rate per gene. If the *de novo* mutations are stratified on the basis of predicted effect (e.g. ‘missense’, ‘nonsense’, etc.), then each gene-annotation category should have its own mutation rate that reflects the predicted effects of the mutations within. In summary, for each gene, we consider four models M_j ($j = 0..3$) reflecting four alternative hypotheses: the gene is associated with neither trait (H_0), the first trait only (H_1), the second trait only (H_2), or both traits (H_3). We assume prior probabilities π_j ($j = 0..3$) for the four models. To build models for these hypotheses, we used single-trait models from TADA (He, et al., 2013); therefore, we first introduce TADA and then mTADA. Like TADA, mTADA divides mutations into different annotation categories (e.g., loss-of-function or missense variants), builds models for these categories, and then integrates information across models to infer results.

In TADA, for the single trait k , for each variant/mutation category in each gene, all variants are collapsed and considered as one count (x_k) with $x_k \sim \text{Poisson}(2N_k\mu\gamma_k)$, in which N_k , μ and γ_k are the sample size (family number), mutation rate and relative risk (RR) of the category. For a single trait, TADA compares two hypotheses for each gene: non-risk gene $\gamma_k = 1$, and risk gene $\gamma_k > 1$ in which γ_k follows a Gamma distribution: $\gamma_k \sim \text{Gamma}(\bar{\gamma}_k\beta_k, \beta_k)$ with $\bar{\gamma}_k$ being the mean relative risk (meanRR) across risk genes, and β_k being a dispersion parameter. Thus, TADA implies that a proportion of all genes (π_k^S) are risk genes. In mTADA, with two traits and four models, we define γ_k as the non-null RR for trait k ($k = 1, 2$), which we can describe in terms of $\gamma_{k,j}$ for trait k under the j^{th} model as $\gamma_1 = \gamma_{1,1} = \gamma_{1,3} > 1$ for the first trait, and $\gamma_2 = \gamma_{2,2} = \gamma_{2,3} > 1$ for the second trait (Table 1). Under the non-risk gene models for each trait, $\gamma_{1,0} = \gamma_{2,0} = \gamma_{2,1} = \gamma_{1,2} = 1$.

The likelihood of the data across all N genes can be computed as $L = \prod_{i=1}^N \sum_{j=0}^3 \pi_j P_{ij}^1 P_{ij}^2$ with $P_{ij}^k = P(x_{ki} | \phi_{kj})$, where x_{ki} and ϕ_{kj} are the i^{th} gene data and j^{th} model parameters for trait k ($k = 1, 2$). In addition, if the data include multiple categories of variants then $P_{ij}^k = \prod_{l=1}^{n_c} P_{ij}^{k_l}$ with n_c being the number of categories.

Hypothesis	Proportion	First trait	Second trait
H_0 : gene is associated with neither trait	π_0	$x_1 \sim \text{Poisson}(2N_1\mu)$	$x_2 \sim \text{Poisson}(2N_2\mu)$
H_1 : gene is associated with the first trait	π_1	$x_1 \sim \text{Poisson}(2N_1\mu\gamma_1)$ $\gamma_1 \sim \text{Gamma}(\bar{\gamma}_1\beta_1, \beta_1)$	$x_2 \sim \text{Poisson}(2N_2\mu)$
H_2 : gene is associated with the second trait	π_2	$x_1 \sim \text{Poisson}(2N_1\mu)$	$x_2 \sim \text{Poisson}(2N_2\mu\gamma_2)$ $\gamma_2 \sim \text{Gamma}(\bar{\gamma}_2\beta_2, \beta_2)$
H_3 : gene is associated with both traits	π_3	$x_1 \sim \text{Poisson}(2N_1\mu\gamma_1)$ $\gamma_1 \sim \text{Gamma}(\bar{\gamma}_1\beta_1, \beta_1)$	$x_2 \sim \text{Poisson}(2N_2\mu\gamma_2)$ $\gamma_2 \sim \text{Gamma}(\bar{\gamma}_2\beta_2, \beta_2)$

Table 1: Statistical models for four hypotheses in mTADA for one category of variants in each trait. For each gene, mTADA assumes that the gene can be in one of four models $M_0..M_3$. π_j ($j = 0..3$) is the prior probability of the j^{th} model. x_k and N_k ($k = 1, 2$) are the data and the sample size of the k^{th} trait. μ is the mutation rate of the gene; γ_k and $\bar{\gamma}_k$ are the relative risk and mean relative risks of the variant category. Grey and blue cells describe models for risk and non-risk genes respectively.

2.1.2 Estimation of the parameters

We used our single-trait pipeline, extTADA, to estimate the proportions of risk genes (π_1^S and π_2^S), mean relative risks ($\bar{\gamma}_1^S$ and $\bar{\gamma}_2^S$) and dispersion parameters (β_1^S and β_2^S) for each single trait (described as the superscript). We used these values inside mTADA: $\pi_1 = \pi_1^S - \pi_3$, $\pi_2 = \pi_2^S - \pi_3$, and $\pi_0 = 1 - (\pi_1^S + \pi_2^S - \pi_3)$ because of $\sum_{j=0}^3 \pi_j = 1$. We also assumed that $\bar{\gamma}_1 = \bar{\gamma}_1^S$; $\bar{\gamma}_2 = \bar{\gamma}_2^S$; $\beta_1 = \beta_1^S$ and $\beta_2 = \beta_2^S$. Therefore, we only estimated π_3 inside mTADA. Bayesian models were built using the *rstan* package (Carpenter, et al., 2016). We used Markov Chain Monte Carlo (MCMC) within *rstan* to estimate π_3 . We also implemented another option for users to choose the automatic differentiation vibrational inference (ADVI) (Kucukelbir, et al., 2015) to estimate π_3 . Convergence was diagnosed by the estimated potential scale reduction statistic ($\hat{R}$) and visualizing traces of results. The *Locfit* package (Loader, 2007) was used to obtain the mode, credible interval (CI) of π_3 . We used the mode as the estimated value of π_3 .

2.1.3 Inference of risk genes

For gene i , the statistical support for the j^{th} model is captured by its posterior probability ($PP_{ij} = \frac{\pi_j P_{ij}^1 P_{ij}^2}{\sum_{m=0}^3 \pi_m P_{im}^1 P_{im}^2}$, abbreviated as PP0, PP1, PP2 or PP3 for a gene). Inference of risk genes

shared by the two traits can be made based on PP3. To summarize the evidence for association with a given trait, we used the sum of posterior probabilities of models including the risk gene hypothesis for that trait (Barber, et al., 2010), i.e. $PP_{i1} + PP_{i3}$ for trait one and $PP_{i2} + PP_{i3}$ for trait two. In this way, we can clearly see how trait two's data's support for risk genes may contribute to support for trait one.

2.2 Simulation analysis

2.2.1 Generation of simulated data

We simulated data under the mTADA model in Table 1. A gene was assigned to one of the four groups (four models) by using the probability $(\pi_0, \pi_1, \pi_2, \pi_3)$. We used $\pi_1^S = 0.05$ and $\pi_2^S = 0.03$ which are approximately equal to ASD, ID and DD results in our single-trait study (Nguyen, et al., 2017). π_3 was simulated with different values between 0 to $\min(\pi_1^S, \pi_2^S)$, and π_0, π_1 and π_2 were calculated as in the previous section. A range of meanRRs were simulated for each of the two traits. Two mutation categories were simulated for each trait; therefore, there were four meanRRs for the two traits. We simulated 100 values of each combination of $\pi_3, \bar{\gamma}_1$ and $\bar{\gamma}_2$ and calculated the mean of these 100 simulation results.

2.2.2 Validation of parameter inference and risk gene discovery

To calculate Type I error, we simulated different combinations of genetic parameters with $\pi_3 = 0$. For each PP threshold, if there were at least one significant overlapping gene ($PP3 > \text{the PP threshold}$) then the error was calculated.

We used simulated data to assess the correlation between true and observed π_3 values and between PPs and observed false discovery rates (oFDRs). An oFDR at a PP threshold was defined as the number of false positive genes divided by the number of identified genes. To use mTADA for single traits, for the i^{th} gene, we calculated $PP_{i1} + PP_{i3}$ and $PP_{i2} + PP_{i3}$ for the first and second trait respectively.

2.2.3 Comparison between single-trait and two-trait pipelines

We used AUCs (area under the Receiver Operating Characteristic (ROC) curve) to compare risk gene classification performance between mTADA and extTADA on single traits. To obtain AUCs, we calculated true and false positive rates for extTADA and mTADA across PP thresholds, and calculated the areas under these ROC curves. We set a threshold of $PP=0.8$ to compare gene counts between mTADA and extTADA.

2.3 Neuropsychiatric disease and congenital heart disease de novo mutation data

We used the DNM data collected by Nguyen, et al. (2017) and CHD data from Homsy, et al. (2015). These data included 356 EPI trios, 5122 ASD trios, 4293 DD trios, 1012 ID trios, 1017 SCZ trios, and 1213 CHD trios. DNMs were annotated and classified into multiple categories as in our previous work (Nguyen, et al., 2017). For NDDs (EPI, ASD, DD and ID) and CHD, we used two categories (Nguyen, et al., 2017): loss-of-function (LoF) and missense damaging (MiD) DNMs. The LoF category included nonsense, essential splice site, and frameshift DNMs defined by Plink/Seq (Fromer, et al., 2014) while the MiD category included DNMs annotated as missense by Plink/Seq and predicted damaging by each of seven methods (Genovese, et al., 2016): SIFT, Polyphen2_HDIV, Polyphen2_HVAR, LRT, PROVEAN, MutationTaster, and MutationAssessor. For SCZ, we used LoF, MiD and synonymous mutations within DNase I

hypersensitive sites (DHSs) because this category showed significant DNM enrichment in SCZ probands (Takata, et al., 2016) and non-null meanRR in extTADA (Nguyen, et al., 2017). Mutation rates were calculated as described by Fromer, et al. (2014) and Nguyen, et al. (2017). extTADA was used to obtain the proportions of risk genes and the meanRR of each category for each disorder. These values were then used as input for mTADA to estimate π_3 and then calculate PP_{ij} ($i = 1..N, j = 0..3$) for each pair of traits.

The MCMC algorithm, No-U-Turn Sampler (NUTS), in the *rstan* package was used to estimate π_3 . Two independent chains and 5000 steps for each chain were used in the sampling process. Only 1000 samples from each chain were chosen for further analyses.

We used results from new de novo studies to validate mTADA results. New CHD de novo data include 2,871 probands which consist of 2445 trios (1204 trios are inside the data set of extTADA and used in the primary analysis of this study) and 226 singletons (Jin, et al., 2017). In addition, we used the whole-genome-sequencing (WGS) trio data for EPI (Hamdan, et al., 2017) to validate results of EPI, which include 197 trios not included in our mTADA analyses.

For further in silico validation and characterization genes identified by mTADA, GeNets (Li, et al., 2017) was used to test protein-protein interactions (PPIs). The STRING database (Szklarczyk, et al., 2017) was also used as an alternative source for PPIs. For GeNets, we used results from input genes and direct-connection candidate genes automatically inferred by GeNets. For STRING, we used input genes only to obtain final results. To examine expression information of identified genes, spatiotemporal transcriptomic data were obtained from BRAINSPAN (Miller, et al., 2014), divided into eight developmental time points (four prenatal and four postnatal) (Lin, et al., 2015), and analyzed by hierarchical clustering for developmental trajectories.

To test the significance of the overlap of two gene sets, a permutation approach was used. We chose two random gene sets whose lengths are the same as the two tested gene sets from the background genes (19358 genes from mTADA). This was carried out N times ($N = 10,000$ in this study) and the numbers of overlapping genes were recorded in a vector $\mathbf{m}$. P value was calculated as $(length(\mathbf{m}[\mathbf{m} > m_0]) + 1) / (length(\mathbf{m}) + 1)$ in which m_0 is the observed number of overlapping genes between the two tested gene sets.

3. Results

Because mTADA is a novel tool that analyzes multiple traits using *de novo* mutation and mutation rate data, we validated mTADA using data simulated under its model (Table 1) and compared gene-identification results with our a single-trait pipeline extTADA.

3.1 Results of mTADA on simulated data

We used $\pi_1^S = 0.05$ and $\pi_2^S = 0.03$ as described in the Method section and simulated different data sets from the combination of different values of π_3 and MeanRRs.

3.1.1 Type I error of shared risk gene identification

We first estimated Type I error for identifying shared risk genes (i.e. associated with both traits). We simulated data with $\pi_3 = 0$ and tested for shared risk genes using different thresholds of the posterior probability of Model III (PP3). Smaller PP3 thresholds correspond to increased Type I

error levels. This error was smaller than 0.05 when $PP_3 > 0.8$ (Figure 1A). Overall, the error decreased when meanRRs or sample sizes increased.

3.1.2 Correlations between posterior probabilities and observed false discovery rates.

We also calculated the correlation between PPs and observed FDRs (oFDRs) for all situations. Regarding PP_3 and oFDRs, $PP=0.8$ and 0.5 were approximately with $oFDR=0.1$ and 0.25 respectively. Small meanRRs could create higher FDRs, but this affection was not very strong (Figure 1B). These results were also similar for other situations: genes were associated with only first trait, only second trait, single traits (e.g., only first trait and both traits) (Figure S1, S2).

Figure 1: Validation of shared risk gene identification using mTADA on simulated data. Left panels show the Type I error of the identification of risk genes for both traits: X-axes are posterior probabilities (PPs) of Model III while Y-axes are Type I errors. Right panels show the correlation between PPs (x axis) and observed false discovery rates (FDRs, y axis). These are for the combination of different sample sizes (n_{trio}) and mean relative risks (MeanGamma). n_{trio} and MeanGamma describe the information of two traits.

The correlation between simulated and estimated values of π_3 was also assessed. For large meanRRs, high correlations were observed for all sample sizes. For smaller meanRRs (range here), π_3 values were over- or underestimated (Figure S3). However, these small differences were not much affected to main analyses (Figure 1, S1, S2).

3.1.3 Power for single-trait risk gene discovery

We compared gene numbers identified by mTADA and extTADA using the same threshold $PP > 0.8$. For $\pi_3 = 0$ (no overlapping information), mTADA and extTADA reported nearly the same positive gene numbers (Figure 2A). However, mTADA identified more genes than extTADA

when π_3 increased. In addition, mTADA's gene counts were also higher than those of extTADA when higher meanRRs were used.

Figure 2: Results of simulated data for single traits. Right panels show AUC (area under the Receiver Operating Characteristic (ROC) curve) results of mTADA and extTADA while left panels describe positive gene counts with PPs > 0.8. MeanGamma, ntrio and π_3 describe for mean relative risks, sample sizes and the proportions of overlapping genes. ntrio and MeanGamma describe the information of two traits.

3.1.4 Comparison of AUCs for single traits

We designed a simulation experiment to assess the performance in the classification of risk and non-risk genes. We applied extTADA to single-trait data from our simulated data. We then calculated AUCs for mTADA and extTADA using classification results from single-trait data. AUCs of both were equal when $\pi_3 = 0$ (Figure 2B). However, AUCs of mTADA were higher than those of extTADA when π_3 's values were larger. In addition, mTADA also performed better extTADA with larger meanRRs.

3.2 Results of mTADA and extTADA on neuropsychiatric disease and CHD data

mTADA was applied to family data of 15 pairs of six disorders (ASD, SCZ, DD, ID, EPI and CHD). A threshold PP > 0.8 was used to prioritize top genes. To compare between mTADA and extTADA, we also extracted top prioritized genes from extTADA using the same threshold PP > 0.8.

DD based results showed strong convergence with smaller credible intervals because of its large sample size as well as a high relative risks of DNMs (Figure 3). The highest π_3 was observed for pairs of DD, ID, ASD and CHD ($\pi_3 > 0.019$). These disorders also had the highest percentage of genes that overlap if we only focused on gene risk-gene proportions (Figure 3). CHD and EPI had the lowest π_3 (0.001) followed by SCZ-EPI (0.0023). Figure S4 shows sampling results of

the proportions of overlapping genes for each pair of these traits; and Table S1 describes results of π_1^S , π_2^S estimated by extTADA and π_3 estimated by mTADA.

Regarding overlapping genes, the highest number was also observed for DD and ID (88 genes) followed by ASD-DD (67 genes) and ASD-ID (47 genes). Four pairs of traits (CHD-EPI, SCZ-EPI, CHD-SCZ, SCZ-ID) had no overlapping genes. In comparison with extTADA in the identification of overlapping genes, mTADA reported higher or equal gene numbers (Figure 3). Table S2 shows full mTADA's results for these six disorders.

We also used mTADA to prioritize top genes for single traits and compared with extTADA. For DD and ID, mTADA always performed better extTADA (Figure 3). Similar results were also observed for ASD; except for the pair ASD-SCZ in which mTADA was better than extTADA for SCZ but extTADA was better than mTADA for ASD. For CHD, EPI and SCZ, mTADA was better than extTADA when CHD was combined with DD.

Figure 3: Results of real data. A) Estimated results of the overlapping proportion of risk genes (π_3) for 15 pairs of 6 disorders: schizophrenia (SCZ), congenital heart disease (CHD), intellectual disability (ID), developmental disorder (DD), autism spectrum disorder (ASD), epilepsy (EPI). The first, second and third panels shows the proportion of risk genes that overlap for two traits ($= \pi_3 / (\pi_1 + \pi_2 + \pi_3)$), first trait only ($= \pi_3 / (\pi_1 + \pi_3)$) and second trait only ($= \pi_3 / (\pi_2 + \pi_3)$) while the fourth panel is π_3 . **B)** mTADA's and extTADA's results for all pairs of disorders by using posterior probabilities > 0.8 . Numbers in cells are number of risk genes. For

example, for the pair of DD and ID, mTADA's results are: 3, 4 and 88 genes for Model 1, 2 and 3 respectively; 173 and 101 genes for DD and ID in that order.

Gene Name	ASD-DD	ASD-EPI	ASD-ID	CHD-ASD	CHD-DD	CHD-EPI	CHD-ID	CHD-SCZ	DD-EPI	DD-ID	ID-EPI	SCZ-ASD	SCZ-DD	SCZ-EPI	SCZ-ID
POGZ	1.00	0.14	1.00	0.97	0.99	0.01	0.99	0.46	0.17	1.00	0.27	0.82	0.86	0.02	0.75
SCN2A	1.00	1.00	1.00	0.22	0.50	0.03	0.36	0.02	1.00	1.00	1.00	0.82	0.85	0.75	0.73
ARID1B	1.00	0.08	1.00	0.89	0.97	0.00	0.94	0.02	0.09	1.00	0.15	0.16	0.19	0.00	0.10
GABRB3	0.98	0.99	0.94	0.28	0.61	0.06	0.28	0.00	1.00	0.98	0.99	0.14	0.20	0.14	0.06
KCNQ2	0.82	0.87	0.90	0.05	0.66	0.05	0.51	0.00	1.00	1.00	1.00	0.02	0.22	0.13	0.11
STXBP1	0.98	0.99	0.99	0.23	0.65	0.05	0.49	0.00	1.00	1.00	1.00	0.12	0.22	0.13	0.11
TLK2	0.98	0.09	0.99	0.85	0.96	0.01	0.95	0.05	0.13	1.00	0.22	0.23	0.31	0.00	0.19
CHD2	1.00	0.80	1.00	0.41	0.72	0.02	0.56	0.00	0.82	1.00	0.88	0.16	0.19	0.02	0.10
CTNNB1	0.84	0.01	0.92	0.39	0.97	0.00	0.95	0.03	0.13	1.00	0.21	0.03	0.22	0.00	0.12
MLL	0.91	0.60	0.89	0.08	0.60	0.02	0.34	0.00	0.91	1.00	0.92	0.03	0.16	0.03	0.07
SYNGAP1	1.00	0.08	1.00	0.32	0.63	0.00	0.48	0.03	0.09	1.00	0.15	0.83	0.86	0.01	0.74
CACNA1A	0.09	0.11	0.03	0.01	0.95	0.34	0.70	0.01	1.00	0.98	0.98	0.00	0.17	0.10	0.04
KCNQ3	0.93	0.78	0.78	0.11	0.67	0.03	0.24	0.00	0.95	0.98	0.92	0.05	0.22	0.07	0.06
MED13L	0.90	0.01	0.95	0.19	0.82	0.00	0.72	0.01	0.06	1.00	0.09	0.03	0.20	0.00	0.10

Table 2: Genes with the posterior probabilities (PPs) of Model 3 (two traits) > 0.8. These genes appear in at least 4 pairs of disorders. Cells shows the PP values.

Insights into top mTADA genes

Overlapping genes between two traits

Using a threshold $PP > 0.8$, 153 genes were supported by the two-trait model in at least one pair ($\pi_3 > 0.8$, Table S2). Seven genes (*ARID1B*, *GABRB3*, *KCNQ2*, *STXBP1*, *SYNGAP1*, *TLK2*, *POGZ*, *SCN2A*) were observed for at least six pairs of disorders (Table 2). *POGZ* and *SCN2A* were present in eight pairs of disorders. *POGZ* was significant for pairs relating to ASD, DD, ID, CHD and SZ while *SCN2A* was significant for pairs relating to ASD, DD, EPI, ID and SCZ. We checked DNMs of these two genes. As expected, *POGZ* had no DNMs for CHD, and *SCN2A* had no DNMs for EPI. Interestingly, in the latest CHD study (Jin, et al., 2017), *POGZ* was one of the top CHD gene while no DNMs were observed for *SCN2A*. In addition, in the latest study of 6,753 parent-offspring trios with NDDs and EPI (Heyne, et al., 2018), 16 DNMs were in *POGZ*, but only one DNM was from a patient who has both ID and EPI.

Significant genes of single traits

To better understand mTADA results, we focused on three disorders (EPI, CHD and SCZ) whose DN-based genes have not been reported as many as the three other disorders. We used the $PP_{ik} + PP_{i3}$ ($k = 1, 2$) of mTADA to obtain a single-trait's PP for the i^{th} gene in the analysis of each pair of two disorders. We used DD as the main trait to infer results of other trait.

CHD

There were 31 genes with $PP > 0.8$ by combining CHD and DD. 20/31 was not in the list of known CHD genes and in the meta-analysis results of a recent CHD study of Jin, et al. (2017) (Figure 4). We tested the PPIs of these 31 genes by using GeNets and STRING database. Based on GeNets, these genes were well connected to communities (Overall connectivity $p < 2.2 \times 10^{-3}$, Figure 4). Next, by using STRING database, the number of edges were also higher than expected between these 31 nodes (20 edges versus 9 expected edges, $p = 0.00198$). We used expression data to test these genes. The majority of these genes were strongly expressed in early to late-mid prenatal stages (Figure 4).

Validation of CHD genes using an independent data set

We used the data of Jin, et al. (2017) to validate these results (See Methods). First, we tested the top CHD genes from the independent data set which include 1241 trios and 226 cases from Jin, et al. (2017). From the 1241 trios, three genes (CTNNB1, CUL3, LZTR1) of the 20 novel genes had LoF or MiD DNMs ($p < 2.00 \times 10^{-4}$, Figure 4). In addition, CUL3 had one LoF variant from case data. These three genes had only one DNMs in the primary analysis, and were not called as significant genes by extTADA. We also ran extTADA on the 1241 trios, and saw that 4 of the 31 genes had $PP > 0.8$ (Figure 4). As expected, extTADA results of the majority of these 31 genes had low PPs because these genes had only 0 or 1 DNMs. Next, we compared our 31 genes with the top 25 genes meta-analyzed by Jin, et al. (2017). 8/31 were in the 25-gene list ($p < 9.99 \times 10^{-5}$).

To better understand the performance of mTADA on the combination of CHD and other disorders, we applied mTADA to the independent data set only and the combined data set. First, we ran mTADA on the independent 1241-trio data. Similar to the primary analysis, we also saw high overlaps between CHD, ASD, DD and ID (Figure 4). By combining CHD and DD, 24 genes had $PP > 0.8$. There were 6 overlapping genes between the 31 genes and the 24 genes ($p < 9.99 \times 10^{-5}$). In these six genes, two genes NSD1 and CTNNB1 showed the benefit of using mTADA. Both genes had only one LoF DNM and did not show significant results in the original study of 1204 trios (Homsy, et al., 2015) as well as extTADA, but had highly significant PPs from mTADA ($PP > 0.97$). Next, mTADA was applied to full 2451 trios. Estimated π_3 values were similar to those of 1204 trios (Figure 4). There were 57 genes with $PP > 0.8$. 19/57 genes were in the 31 genes ($p < 9.99 \times 10^{-5}$).

There were 10 genes with PP>0.8 including AUTS2, BRPF1, HIST1H1E, MAP4K4, MKI67, POGZ, SCN2A, SETD1A, SYNGAP1, TAF13. These were significantly connected to

communities by the PPI analysis (Overall connectivity $p < 2.2 \times 10^{-3}$, Figure S6) by using GeNets. These genes were not strongly connected by using STRING database (1 edges versus 0 expected edges, $p = 0.22$). In these genes, only TAF13 and SETD1A were suggested as top genes in previous study (Fromer, et al., 2012; Nguyen, et al., 2017). In addition, AUTS2 (PP>0.8) was reported as a SCZ genes from a common variant based study (Zhang, et al., 2014). Using expression data, multiple genes of these genes were expressed in prenatal stages, but the signals were as not strong as those of CHD (Figure S6).

4. Discussion

In this paper, we propose a method to jointly analyze two traits (mTADA) using *de novo* exome sequencing data. The method is an extension of our previous work for single traits (He, et al., 2013; Nguyen, et al., 2017). mTADA estimates the proportion of overlapping genes between two traits, and then uses this information to infer how many overlapping genes exist between two traits. The pipeline is also able to infer the number of risk genes for each trait by calculating posterior probabilities (PPs) of genes for each trait. On simulated data, mTADA performs better than extTADA on the identification of risk genes. We also applied mTADA to more than 13,000 trios of five disorders and reported overlapping genes between these disorders. We also saw that mTADA reported more risk genes for these disorders than extTADA. This suggests that mTADA can help in the identification of additional risk genes, especially for disorders whose large sample sizes are challenging to obtain or whose mean relative risks are small. For such disorders, users can combine the data of the disorders with large public data sets (e.g., trio data of ASD, DD) to prioritize risk genes. Using one-trait information to leverage the information for other traits has been successful in fine-mapping (Kichaev, et al., 2017) and common-variant (Maier, et al., 2018) studies. Based on our best knowledge, mTADA is the first tool using this approach for *de novo* mutation data. We hope that mTADA (<https://github.com/hoangtn/mTADA>) will be generally useful for analyzing *de novo* mutation data across complex traits.

By using mTADA, multiple overlapping genes were observed for CHD, DD, ID and ASD. This replicates a recent study (Homsy, et al., 2015) in which high overlapping genes were observed for CHD and neurodevelopmental disorders (NDDs). Interestingly, CHD did not show any overlapping information with another NDD: epilepsy (EPI). Two genes SCN2A and POGZ which have been reported as risk genes for some of these disorders (Stessman, et al., 2016; White, et al., 2016; Ben-Shalom, et al., 2017; Jin, et al., 2017) are top overlapping genes from mTADA (Table S2), but they show different trends. No SCN2A DNMs are in CHD data and no POGZ DNMs are in EPI data. One possible reason is that the sample size of EPI is small in this study (356 trios). Another hypothesis might be because they do not have strong overlapping biological pathways. We did not see any overlapping information between SCZ and CHD as well as SCZ and CHD. We analyzed in depth the top prioritized genes of CHD, EPI and SCZ (Figure 4, S5-6). Top risk CHD and EPI genes from mTADA are also reported in recent study (Hamdan, et al., 2017; Jin, et al., 2017). Multiple top CHD genes have only one DNM, but have DNMs or variants in independent data sets (Figure 4). This suggests that they might be real risk-genes for this disorder. Interesting, we identify 20 novel CHD genes (posterior probabilities > 0.8) and 3 of these 20 genes have DNMs in an independent data set. This shows the benefit of using mTADA in the prediction of risk genes for CHD by borrowing the information of DD. CHD genes are

strongly expressed in pre-natal stages of the human brain (Figure 4).

Although mTADA performs better than the single-trait based extTADA, it does have some limitations. mTADA uses the parameters of single traits from extTADA to infer the proportion of overlapping genes (π_3). Using parameters from extTADA makes mTADA much faster in its calculation, it means mTADA relies on the results of the single-trait pipeline extTADA that uses a full Bayesian approach. Also, mTADA as well as extTADA use *de novo* counts for each gene and divide these counts into different categories similar to other rare variant based studies (Sanders, et al., 2012; De Rubeis, et al., 2014; Genovese, et al., 2016; Allen, et al., 2017). Future studies which are able to incorporate the annotation information of each DNM may increase the power of mTADA or similar tools.

With further development, the mTADA approach can be generalized further to consider more than two traits simultaneously, and the increased information could increase the number of identified risk genes but at a cost of increased computational time.

In conclusion, mTADA can be very useful for better understanding the genetic correlation across disorders (via the proportion of overlapping genes), and to prioritize additional risk genes for disorders. The approach of mTADA can be used to identify shared/specific risk genes for different categories of one trait (e.g., loss of function and missense *de novo* mutations). Genetic information of *de novo* mutations and rare case/control variants can be different (Sifrim, et al., 2016), mTADA might be adopted to pipelines which are able to apply to DNMs and rCCVs as two traits.

Author's contributions

Designed the pipeline used in analysis; performed the experiments, analyzed the data and drafted the manuscript: HTN. Conceived and designed the experiments: HTN, EAS. Contributed reagents/materials/analysis tools: HTN, AD, DP, JB, XH, PFS, EAS. Wrote the paper: HTN, AD, PFS, XH, EAS.

Acknowledgements

This work is supported by NIH grant R01MH105554 to E.A.S., and by NIH grant R01MH110555 to D.P. The Sweden exome sequencing data generation and analysis are supported by the Stanley Center for Psychiatric Research and NIH grant R01 MH077139 to P.F.S. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. We are deeply grateful for the participation of all subjects contributing to this research.

Allen, A.S., *et al.* Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. *The Lancet Neurology* 2017;16(2):135-143.

Allison, D.B., *et al.* Multiple phenotype modeling in gene-mapping studies of quantitative traits: power advantages. *Am J Hum Genet* 1998;63(4):1190-1201.

Barber, M.J., *et al.* Genome-wide association of lipid-lowering response to statins in combined study populations. *PLoS One* 2010;5(3):e9763.

- Ben-Shalom, R., *et al.* Opposing Effects on NaV1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures. *Biol Psychiatry* 2017;82(3):224-232.
- Carpenter, B., *et al.* Stan: A probabilistic programming language. *Journal of Statistical Software* 2016;20(2):1-37.
- De Rubeis, S., *et al.* Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* 2014;515(7526):209-215.
- Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. *Nature* 2017;542(7642):433-438.
- Fromer, M., *et al.* Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. *Am J Hum Genet* 2012;91(4):597-607.
- Fromer, M., *et al.* De novo mutations in schizophrenia implicate synaptic networks. *Nature* 2014;506(7487):179-184.
- Galesloot, T.E., *et al.* A comparison of multivariate genome-wide association methods. *PLoS One* 2014;9(4):e95923.
- Genovese, G., *et al.* Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. *Nature neuroscience* 2016;19(11):1433.
- Giambartolomei, C., *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS genetics* 2014;10(5):e1004383.
- Hamdan, F.F., *et al.* High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. *Am J Hum Genet* 2017;101(5):664-685.
- He, X., *et al.* Integrated model of de novo and inherited genetic variants yields greater power to identify risk genes. *PLoS Genet* 2013;9(8):e1003671.
- Heyne, H.O., *et al.* De novo variants in neurodevelopmental disorders with epilepsy. *Nat Genet* 2018;50(7):1048-1053.
- Hoischen, A., Krumm, N. and Eichler, E.E. Prioritization of neurodevelopmental disease genes by discovery of new mutations. *Nature neuroscience* 2014;17(6):764.
- Homsy, J., *et al.* De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. *Science* 2015;350(6265):1262-1266.
- Iossifov, I., *et al.* The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014;515(7526):216-221.
- Jin, S.C., *et al.* Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. *Nat Genet* 2017;49(11):1593-1601.
- Kichaev, G., *et al.* Improved methods for multi-trait fine mapping of pleiotropic risk loci. *Bioinformatics* 2017;33(2):248-255.
- Kucukelbir, A., *et al.* Automatic variational inference in Stan. In, *Advances in neural information processing systems*. 2015. p. 568-576.
- Lelieveld, S.H., *et al.* Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nat Neurosci* 2016;19(9):1194-1196.
- Li, J., *et al.* Genes with de novo mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database. *Molecular psychiatry* 2016;21(2):290.
- Li, T., *et al.* A scored human protein-protein interaction network to catalyze genomic interpretation. *Nat Methods* 2017;14(1):61-64.
- Lin, G.N., *et al.* Spatiotemporal 16p11.2 protein network implicates cortical late mid-fetal brain development and KCTD13-Cul3-RhoA pathway in psychiatric diseases. *Neuron* 2015;85(4):742-754.

- Loader, C. Locfit: Local regression, likelihood and density estimation. *R package version* 2007;1.
- Lutz, S.M., *et al.* A general approach to testing for pleiotropy with rare and common variants. *Genetic epidemiology* 2017;41(2):163-170.
- Maier, R.M., *et al.* Improving genetic prediction by leveraging genetic correlations among human diseases and traits. *Nat Commun* 2018;9(1):989.
- Miller, J.A., *et al.* Transcriptional landscape of the prenatal human brain. *Nature* 2014;508(7495):199-206.
- Nguyen, H.T., *et al.* Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders. *Genome Med* 2017;9(1):114.
- Pickrell, J.K., *et al.* Detection and interpretation of shared genetic influences on 42 human traits. *Nature genetics* 2016;48(7):709-717.
- Sanders, S.J., *et al.* De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature* 2012;485(7397):237.
- Sifrim, A., *et al.* Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. *Nat Genet* 2016;48(9):1060-1065.
- Solovieff, N., *et al.* Pleiotropy in complex traits: challenges and strategies. *Nat Rev Genet* 2013;14(7):483-495.
- Stessman, H.A.F., *et al.* Disruption of POGZ Is Associated with Intellectual Disability and Autism Spectrum Disorders. *Am J Hum Genet* 2016;98(3):541-552.
- Szklarczyk, D., *et al.* The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res* 2017;45(D1):D362-D368.
- Takata, A., *et al.* De Novo Synonymous Mutations in Regulatory Elements Contribute to the Genetic Etiology of Autism and Schizophrenia. *Neuron* 2016;89(5):940-947.
- Turley, P., *et al.* Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nature genetics* 2018;1.
- White, J., *et al.* POGZ truncating alleles cause syndromic intellectual disability. *Genome Med* 2016;8(1):3.
- Willsey, A.J., *et al.* The Psychiatric Cell Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular Pathways in Neuropsychiatric Disorders. *Cell* 2018;174(3):505-520.
- Zhang, B., *et al.* Association study identifying a new susceptibility gene (AUTS2) for schizophrenia. *Int J Mol Sci* 2014;15(11):19406-19416.
- Zhernakova, A., *et al.* Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. *PLoS Genet* 2011;7(2):e1002004.